FMI
BMRN icon

F/M Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

F/M Investments’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-22,073
Closed -$1.56M – 403
2024
Q3 		$1.56M Buy
+22,073
New +$1.85M 0.05% 235

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

F/M Investments's BMRN Position: Q4 2024 in Review

F/M Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 22,073 shares — an estimated $1.56M sold.

F/M Investments first reported a position in BMRN in Q3 2024 and held it in 1 quarter. The position peaked at $1.56M in Q3 2024. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

  • F/M Investments reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • F/M Investments sold 22,073 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $1.56M.
  • F/M Investments first reported a position in BioMarin Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • F/M Investments's BioMarin Pharmaceuticals position peaked at $1.56M in Q3 2024.
  • 543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on F/M Investments's 13F filing for Q4 2024, filed 13 Feb 2025.